Last reviewed · How we verify
NCT03333551
Cardiac Uptake of 18F Florbetapir in Patients Undergoing Chemotherapy
Phase 4 trial testing F18 Florbetapir (amyvid) cardiac PET/CT imaging in Cardiac Amyloidosis in 3 participants. Terminated before completion.
8 May 2023
Quick facts
| Lead sponsor | Medical College of Wisconsin |
|---|---|
| Phase | Phase 4 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 3 |
| Start date | 1 October 2020 |
| Primary completion | 8 May 2023 |
| Estimated completion | 8 May 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- F18 Florbetapir (amyvid) cardiac PET/CT imaging — full drug profile →
Conditions studied
- Cardiac Amyloidosis — all drugs for Cardiac Amyloidosis →
Sponsor
Medical College of Wisconsin
Who can join
18 and older, any sex, with Cardiac Amyloidosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a pilot study designed to assess for relative change in cardiac 18F Florbetapir uptake in patients with AL cardiac amyloidosis after appropriate chemotherapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03333551
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cardiac Amyloidosis
Currently open trials in the same condition.
- NCT07232459 — [18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis · recruiting
- NCT06788535 — Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis · Phase 3 · active not recruiting
- NCT06458374 — ATTR Cardiac Amyloidosis in a Selected Population · recruiting
- NCT06427304 — Cardiac Amyloidosis pRevaleNce of in OLDer Subjects Affected by Heart Failure · recruiting
- NCT06907836 — Description of a Retrospective Cohort of Patients With Transthyretin Cardiac Amyloidosis (ATTR-CA) in Internal Medicine · recruiting
Other Medical College of Wisconsin trials
Trials by the same sponsor.
- NCT07260552 — Rapid Engagement for Solutions to Population and Outcomes Through Networked Dialogue for Coronary Heart Disease · not yet recruiting
- NCT06795360 — Weight Changes After Incretin-mimetics · NA · not yet recruiting
- NCT07228208 — Role of Endothelial Dysfunction on Exercise Pressor Reflex in Type 2 Diabetes · NA · not yet recruiting
- NCT07298460 — Stimulation-based Therapy to Improve Balance in DCM · Phase 1, PHASE2 · not yet recruiting
- NCT07434544 — Cardiometabolic Effects of Non-Nutritive Sweeteners (NNS) in Type 1 Diabetes (T1D) · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03333551 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medical College of Wisconsin
- Last refreshed: 9 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03333551.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing